Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation of GEM103 in geographic atrophy
NCT04246866Phase 1Completed
- Sponsor
- Gemini Therapeutics
- Start
- Dec 2019
- Primary completion
- Oct 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of GEM103 in geographic atrophy (GA) (4 arms), sponsored by Gemini Therapeutics. Primary endpoint: Incidence and severity of Adverse Events/Serious Adverse Events at 8 weeks. Started Dec 2019; status: completed.
02
Drugs
GEM103
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT04246866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246866.